Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Mass Balance of Dirozalkib in Healthy Chinese Volunteers
NCT05034120Phase 1Completed
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dirozalkib in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Area under the concentration-time curve from time 0 to the last quantifiable data point up to 192 hours, Maximum measured plasma concentration up to 192 hours and 2 more. Started Dec 2021; status: completed.
02
Drugs
dirozalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05034120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034120.